PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-95.21%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-116.81%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-52.01%
Negative EBIT growth while TRVN is at 10.01%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-52.01%
Negative operating income growth while TRVN is at 10.01%. Joel Greenblatt would press for urgent turnaround measures.
-52.47%
Negative net income growth while TRVN stands at 8.19%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-43.48%
Negative EPS growth while TRVN is at 8.13%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-43.48%
Negative diluted EPS growth while TRVN is at 8.13%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
7.17%
Share count expansion well above TRVN's 0.00%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.17%
Diluted share count expanding well above TRVN's 0.00%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
582.93%
OCF growth above 1.5x TRVN's 34.55%. David Dodd would confirm a clear edge in underlying cash generation.
577.68%
FCF growth above 1.5x TRVN's 34.55%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9508.05%
10Y OCF/share CAGR above 1.5x TRVN's 76.82%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
131.96%
5Y OCF/share CAGR above 1.5x TRVN's 76.96%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
210.81%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
88.12%
Net income/share CAGR 1.25-1.5x TRVN's 73.39%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
91.00%
5Y net income/share CAGR 1.25-1.5x TRVN's 74.14%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
67.11%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
1963.85%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-27.97%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
5.99%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.35%
Asset growth above 1.5x TRVN's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.97%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
1244.16%
Debt growth far above TRVN's 192.14%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
6.71%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
86.34%
We expand SG&A while TRVN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.